Free White Paper

©2015 Advantage Business Media. All rights reserved.

This data may be used by the sponsor to provide you with information within the scope of this white paper. Any information you submit by this form will only be used for the purposes indicated. You can trust Advantage Business Media not to rent, sell, exchange, or give your information to any third party without permission. 

Download Now

Guide for US FDA-Regulated Organizations

In such stringently controlled industries as pharmaceutical/biotechnical/medical device development, manufacturing, and warehousing, receiving a list of deficiencies can feel like a heavy blow to your quality system. The following article shows three excerpts from some of the more common “observations” noted in Form 483 Letters during 2008-2009. None of the deviations excerpted here are unique, but all are avoidable. After the excerpts, the reader will find an outline of the best practices of a 483 response, including a 10-point checklist that should make that 15-day time limit more manageable, links for further research, and some ways to simplify and automate monitoring, alarming and reporting on FDA regulated environments.

Guide for US FDA-Regulated Organizations

Please correct the following errors: